Wednesday, December 28, 2022

Association of periprocedural perfusion non-improvement with recurrent stroke after endovascular treatment for Intracranial Atherosclerotic Stenosis

This says something but I can't tell what.

Association of periprocedural perfusion non-improvement with recurrent stroke after endovascular treatment for Intracranial Atherosclerotic Stenosis

Abstract

Background:

Predictors of recurrent stroke after endovascular treatment for symptomatic intracranial atherosclerotic stenosis (ICAS) remain uncertain.

Objectives:

Among baseline characteristics, lesion features, and cerebral perfusion changes, we try to explore which factors are associated with the risk of recurrent stroke in symptomatic ICAS after endovascular treatment.

Design:

Consecutive patients with symptomatic ICAS of 70–99% receiving endovascular treatment were enrolled. All patients underwent whole-brain computer tomography perfusion (CTP) within 3 days before and 3 days after the endovascular treatment. Baseline characteristics, lesion features, and cerebral perfusion changes were collected.

Methods:

Cerebral perfusion changes were evaluated with RAPID software and calculated as preprocedural cerebral blood flow (CBF) < 30%, time to maximum of the residue function (Tmax) > 6 s, and Tmax > 4 s volumes minus postprocedural. Cerebral perfusion changes were divided into periprocedural perfusion improvement (>0 ml) and non-improvement (⩽ 0 ml). Recurrent stroke within 180 days was collected. The Cox proportional hazards analysis analyses were performed to evaluate factors associated with recurrent stroke.

Results:

From March 2021 to December 2021, 107 patients with symptomatic ICAS were enrolled. Of the 107 enrolled patients, 30 (28.0%) patients underwent balloon angioplasty alone and 77 patients (72.0%) underwent stenting. The perioperative complications occurred in three patients. Among CBF < 30%, Tmax > 6 s, and Tmax > 4 s volumes, Tmax > 4 s volume was available to evaluate cerebral perfusion changes. Periprocedural perfusion improvement was found in 77 patients (72.0%) and non-improvement in 30 patients (28.0%). Nine patients (8.4%) suffered from recurrent stroke in 180-day follow-up. In Cox proportional hazards analysis adjusted for age and sex, perfusion non-improvement was associated with recurrent stroke [hazards ratio (HR): 4.472; 95% CI: 1.069–18.718; p = 0.040].

Conclusion:

In patients with symptomatic ICAS treated with endovascular treatment, recurrent stroke may be related to periprocedural cerebral perfusion non-improvement.

Registration:

http://www.chictr.org.cn. Unique identifier: ChiCTR2100052925.

Introduction

Intracranial atherosclerotic stenosis (ICAS) is one of the most common causes of ischemic stroke worldwide.13 Patients with 70–99% symptomatic ICAS are at high risk of recurrent stroke (12.2%) at 1 year despite aggressive medical management (AMM),4 and especially higher (37%) in those patients with impaired hemodynamics.5 Endovascular treatment remains an alternative therapy for patients with symptomatic ICAS refractory to AMM.68 In two recent multiple registries focusing on endovascular treatment for symptomatic ICAS, the 1-year recurrent stroke declined to 6.3% and 8.5% compared with 20% in Stenting Versus Aggressive Medical Therapy for Intracranial Atherosclerosis (SAMMPRIS) trial.9,10
So far, the predictors of the risk of recurrent stroke after endovascular treatment for symptomatic ICAS remain uncertain. We hypothesize that some baseline characteristics, lesion features, or cerebral perfusion parameters (preprocedural, postprocedural, or periprocedural changes) might be related to the risk of recurrent stroke after endovascular treatment. As for the evaluation of cerebral perfusion parameters, RAPID software (iSchemia View) which is an automatic software for post-processing computer tomography perfusion (CTP) images can quantitatively evaluate cerebral perfusion parameters, and it had been used to identify potential beneficiary with acute large vessel occlusion through endovascular thrombectomy.11,12 Furthermore, RAPID software was used to assess impaired perfusion for patients with ICAS.13
In this study, we collected baseline characteristics, lesion features, and preprocedural and postprocedural cerebral perfusion parameters of patients with symptomatic ICAS treated with endovascular therapy in a high-volume stroke center and evaluated which factors were associated with the 180-day outcome of recurrent stroke.

No comments:

Post a Comment